Some patients who receive targeted drugs or immunotherapy experience significant benefit in terms of tumor shrinkage and longer survival as responders — but many do not (i.e., non-responders). A new study suggests that measuring overactive genes in the blood could help doctors determine which drugs are most likely to benefit individual non-responders.
Martine Rothblatt's United Therapeutics and Robinson Helicopter team up to build hydrogen helicopters to deliver organs with zero-carbon eVTOL flights.
OncoDxRx, a California-based liquid biopsy startup, builds gene expression-powered treatment selection technology that helps clinicians identify the most suitable drugs for individual patients who are not responding to current therapies.
Clinion, a Lifescience technology company based out of the US, UK and India, has won a category award in the 2024 Clinical Trials Arena Excellence Awards.
OncoDxRx announced a new cfmRNA-based MRD assay creatively named OncoMRD (OncoDxRx’s monitoring residual disease), which the company said is based on its in-service patient-derived gene expression signature.
Satisfied Users & 
Approved Press Releases
